Duplex UltraSound afTer Endo Revascularisation - Feasibility Randomised Control Trial (DUSTER)

Phase 1: Feasibility RCT

The study is a multi-site, randomised (1:1), controlled, open label, 2 arm, feasibility trial.

DUSTER will be performed in 3 NHS vascular units at the following NHS Trusts:

• Mid and South Essex NHS Foundation Trust
• Imperial College Healthcare NHS Trust
• Manchester University NHS Trust

These sites comprise two urban and one rural site, in both the North, South and East of the country. This will help understand the effects of travel, ethnicity, and geography on attending appointments. Following NIHR INCLUDE guidance we have costed for translation of study materials / interpreters.

Phase 2: Participant interviews

Participants in the intervention arm will be invited to individual semi-structured interviews with members of the research team. The interviews will be held as per participants' preference on MS Teams, or via telephone, or in person, after a minimum 6 month follow up.

The interviews seek to explore factors affecting adherence and the impact of integrated surveillance on patients. It will apply a Qualitative Descriptive Research (QDR) approach and aims to inquire into the experience of everyday living with chronic limb threatening ischaemia. QDR aims to provide broad insight into phenomena as experienced/lived by individuals and is widely used as the qualitative component in mixed-methodology studies especially in large-scale healthcare intervention studies to identify participants' perceptions of why ultrasound surveillance worked or did not work and how it might be better implemented. Using QDR in this manner can make modifications to how surveillance is delivered in a future HTA study, including behavioural modifications such as educational tools, automated reminders along with intervention modifications e.g. community-based scanning.

Phase 3: Participant and stakeholder focus groups

After the feasibility study, we will invite participants and stakeholders to 2 separate focus groups (face to face or MS teams-hybrid) to discuss potential secondary endpoints for a future HTA application (e.g. amputation free survival, quality of life and cost-effectiveness). These will be co-chaired with our lay co-applicants.

HTA application drafting

If progression criteria are met (see , Phases 1 -3 will feed into a draft HTA application in the final month of the study. The progression criteria are:

• >80% of ultrasound surveillance appointments are attended (>72/90), AND
• >90% completion rate of at least one ultrasound scan component (>81/90), AND
• There is an increase of >10% in re-interventions in ultrasound surveillance arm (>3 patients).

Inclusion criteria

• Adults (18y+) who have had successful lower limb endovascular therapy (angioplasty, stenting, atherectomy, lithotripsy, drug eluting balloon or stent, or combination of above) for chronic limb threatening ischaemia (ischaemic rest pain, ulceration or gangrene with arterial imaging confirming peripheral arterial disease). Technical success is defined as <30% residual stenosis in the treated segments and patient leaving hospital without a major (above ankle) amputation on study leg
• Procedures within the last 3 weeks
• Interventions to iliac, femoral, tibial, and pedal vessels alone or in combination
• Endarterectomy or cutdown is permissible
• Able to give informed consent

Exclusion criteria

• Surgical bypass or endarterectomy alone undertaken
• Patient unfit for or does not want any future revascularisation
• Need for major amputation due to gas gangrene, severe Charcot deformity, extensive tissue loss with unstable foot, severe pedal disease on angiography or patient request
• Patient unwilling or cannot attend further surveillance
• Interventions for claudication or acute limb ischaemia or trauma
• Patients unable to take any form of antiplatelet therapy (aspirin or clopidogrel)
• Prior leg endovascular therapy at same anatomical location in study leg (within 1 year)
• Currently taking part in research that may impact on the results, design, or scientific value of this study or other studies that the potential participant may be taking part in.